Tests atorvastatin for lung inflammation after tuberculosis treatment
Tests atorvastatin against placebo in adults who finished tuberculosis treatment.
Key facts
- Who runs it
- University of Cape Town
- Where
- Observatory, South AfricaSee the site
- Trial code
- Registry title
- Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 220 people, planned
- Started
- 14 Jul 2020
- Expected to end
- 30 Sept 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Atorvastatin 40mg
- Placebo oral tablet
- Record updated
- 23 August 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 65 who finished 24 weeks of standard TB treatment and were declared cured by the South African TB program. It tests whether atorvastatin 40 mg lowers lung inflammation after TB treatment.
- Age
- 18 to 65 years, body weight 50 kg (110 lb) to 90 kg (198 lb)
- Sex
- All sexes
- Disease stage
- Pulmonary TB treated successfully: sputum culture negative at week 16 and TB treatment completed.
- Earlier treatment
- Must have completed a 24-week course of standard TB treatment (4RHZE/2RH). Cannot have used lipid lowering drugs in the last three months or any trial drug in the last 3 months.
- Biomarker or test result
- If HIV-positive: on antiretroviral therapy for at least 12 weeks, HIV viral load suppressed, and CD4 count above 350 cells/µL. Liver, kidney, blood count and creatine kinase tests must be within set limits.
Main reasons for not taking part
- Drug-resistant TB or TB outside the lungs
- Pregnant or planning pregnancy in the next 6 months
- Diabetes
- Taking lipid lowering drugs or immunosuppressive drugs, or allergic to statins
- Acute illness or fever above 38.0 degrees centigrade
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Has completed the written informed consent process prior to undergoing any pre-screening or screening evaluations and willing to undergo HIV testing
- Age 18 to 65 years with body weight from 50 kg to 90 kg
- Clinical response to TB treatment and sputum culture negative at week 16
- Completed a 24-week course of standard TB treatment (4RHZE/2RH)
- Defined as "cured" by the TB Control Program of South Africa; Laboratory parameters within 30 days before enrolment:
- For HIV-infected participants: receiving antiretroviral therapy for at least 12 weeks and suppressed HIV viral load within 30 days prior to enrolment
- For HIV-infected participants: CD4 counts above 350 cells/µL within 30 days prior to enrolment
- AST and ALT <3x upper limit of normal (ULN)
- Creatinine <2x ULN
- Hemoglobin >7.0 g/dL
- Platelet count >50 x109 cells/L
- Creatinine kinase <2x ULN
- Able and willing to return to follow-up
- Willing to have samples, including DNA, stored
- Willing to consistently practice a highly reliable method of pregnancy prevention
Who cannot take part
- Participant receiving any type of lipid lowering agent at the time of screening, within three months prior to screening or likely to require any lipid lowering agent in the near future
- Known allergy or contraindications to the investigational drug or any other statins
- Evidence of drug-resistant TB
- Unable to take oral medications
- Disease complications or concomitant illnesses that may compromise safety or interpretation of trial endpoints, such as known diagnosis of chronic inflammatory condition (e.g. sarcoidosis, rheumatoid arthritis, connective tissue disorder)
- Use of immunosuppressive medications, such as TNF-alpha inhibitors or systemic or inhaled corticosteroids, within the past 2 weeks
- Use of any investigational drug in the previous 3 months
- Alcohol and substance abuse which might interfere with medication adherence during the trial
- Acute illness
- Diabetes as defined by point of care HbA1c≥6.5, random glucose≥200mg/dL (or 11.1mmol/L), fasting plasma glucose≥126mg/dL (or 7.0mmol/L), or the presence of any anti-diabetic agent (including traditional medicines) as a concomitant medicine
- Fever (temperature >38.0 degrees centigrade)
- Extrapulmonary TB, including pleural TB and/or large pleural effusion
- Pregnant or desiring/trying to become pregnant in the next 6 months
- Any person for whom the physician feels this study is not appropriate
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial is currently available in South Africa.
- General Medicine & Global Health, Cape Heart Institute, Faculty of Health Sciences, University of Cape TownObservatory, South AfricaContact: Sandra Mukasa, MDTaking people
About the trial
What the trial wants to find out
This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in HIV-infected and HIV-uninfected adults measured by PET/CT.
The 2 groups in the trial
- Atorvastatin (Arm B)Existing treatment, for comparison
12 weeks of 40 mg atorvastatin therapy per os daily
Treatment: Atorvastatin 40mg
- Placebo (Arm C)Placebo, for comparison
Identical placebo tablet is taken per os daily
Treatment: Placebo oral tablet
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion in HIV-infected and HIV-uninfected Adults Measured by FDG-PET/CT
- Plain-language title
- Tests atorvastatin for lung inflammation after tuberculosis treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT04147286, who can take part
- Record updated
- 23 August 2024